RTKs can activate Ras, a protein that is tethered to the plasma membrane, by causing it to bind GTP. Once activated, Ras can do a variety of things. In this example, it activates an enzymatic cascade ...

In the course of carcinogenesis, cancer cells hijack and rewire cellular programs to acquire selective proliferation, survival, and adaptive advantages 1. Indeed, the RAS/MAP kinase pathway is ...

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...

Patients with NSCLC who underwent RT for spine metastasis and tumor genetic profiling were ascertained. Associations between driver gene mutations incidence of local failure were analyzed, followed by ...

This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.

Verastem Oncology Inc. and Genfleet Therapeutics Ltd. have inked a discovery and development deal to advance three oncology discovery programs targeting RAS pathway-driven cancers. The collaboration ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...

Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...

When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...